HER2 status-Negative Page 2 Posts on Medivizor
Navigation Menu

HER2 status-Negative Posts on Medivizor

Looking for patients with estrogen receptor-positive breast cancer to test a new treatment combination

Posted by on May 11, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...

Read More

Searching for patients with triple negative breast cancer to test a new medication

Posted by on Apr 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 3 trial will investigate the safety and effectiveness of adagloxad simolenin (AGS)/OBI-821 in triple-negative breast cancer (TNBC). The main outcome will be a change in survival without invasive disease. The details Breast cancer (BC) is one of the most common cancers. BC treatment depends on the tumor type....

Read More

Searching for patients with early stage breast cancer to trial a new radiation treatment plan

Posted by on Mar 27, 2019 in Breast cancer | 0 comments

In a nutshell The trial aims to investigate a new way of delivering radiation therapy in women with early-stage breast cancer. This will involve low doses of radiation therapy being aimed at the part of the breast where the tumor is or was. The main outcomes that will be measured are side effects and recurrence rate. This trial is recruiting in Missouri,...

Read More

Olaparib for treating breast cancer that has spread

Posted by on Mar 5, 2019 in Breast cancer | 0 comments

In a nutshell This study determined whether treating breast cancer that has spread (metastatic) with olaparib (Lynparza) resulted in better outcomes and fewer side effects compared to chemotherapy. The study found that treatment with olaparib led to similar survival outcomes compared to chemotherapy.  Some background There are...

Read More

On Living with Breast Cancer: Dr. Kelly Shanahan’s Patient Journey Part 2

On Living with Breast Cancer: Dr. Kelly Shanahan’s Patient Journey Part 2

Posted by on Mar 30, 2018 in Blog, Breast cancer | 4 comments

In From Physician to Patient, I introduced Dr. Kelly Shanahan, a mother, wife, and obstetrician-gynecologist living and working in California. Her life changed with a breast cancer diagnosis. “In 2008, I was diagnosed with early stage breast cancer, stage IIB to be exact. I underwent an aggressive bilateral mastectomy, because   1) as an ob/gyn...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65.  Some background There are several treatment...

Read More

Searching for triple negative breast cancer patients to test the effectiveness of pembrolizumab

Posted by on Oct 30, 2017 in Breast cancer | 0 comments

In a nutshell This phase 3 trial aims to evaluate how effective pembrolizumab (Keytruda) is at treating triple negative breast cancer. The main outcome to be investigated is the invasive disease free survival. Other outcomes include the overall survival (time from treatment until death from any cause) and side effects. This trial is taking place...

Read More